The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trialParminder K. Judge, William G. Herrington, Katherine R. Tuttle et al.|Nephrology Dialysis Transplantation|2024Cited by 66
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) studyPaolo Verdecchia, Giuseppe Di Pasquale, Gregory Y.H. Lip et al.|EP Europace|2017Cited by 19